1Kaliner MA. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionate [J]. Clin Ther, 2006, 28 (3): 319 -331.
2Newman S, Salmon A, Nave R, et al. High lung deposition of 99roTe -labelled ciclesonide administered via HFA -MDI to patients with asthma [J]. Resp Med, 2006, 100 (3) : 375 -384.
3Niphadkar P, Jagarmath K, Joshi JM, et al. Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: A phase Ⅲ, randomized, double - dummy, open - label study [ J ]. Clin Ther, 2005, 27 (11) : 1752 -1763.
4Hansel TT, Benezet O, Kafa H, et al. A multinational, 12 - week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma [J]. Clin Ther, 2006, 28 (6) : 906 - 920.
5Magnussen H, Hofman J, Staneta P, et al. Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma [J]. J Asthma, 2007, 44 (7) : 555 - 563.
6Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma [J]. Pulm Pharmacol Ther, 2006, 19 (6) : 404 -412.
7Lee DK, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high - dose ciclesonide and fluticasone in moderate persistent asthma [J]. Chest, 2005, 127 (3) : 851 -860.
同被引文献28
1Levy ML, Thomas M,Small I, et al. Summary of the 2008BTS/SIGN British guideline on the management of asthma[J]. Prim Care Respir J, 2009, 18(Suppl 1); S1-S16.
2Kaur M, Holden NS, Wilson SM, et al. Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents oninflammatory gene expression in human ASM cells: a role forprotein kinase A [J]. Am J Physiol Lung Cell Mol Physiol,2008,295(3): L505-L514.
3Salter M, Biggadike K, Matthews JL, et al. Pharmacologicalproperties of the enhanced-affinity glucocorticoid fluticasonefuroate in vitro and in an in vivo model of respiratoryinflammatory disease [J]. Am J Physiol Lung Cell MolPhysiol, 2007, 293(3): L660-L667.
4Kroegel C, Wirtz H. History of guidelines for the diagnosisand management of asthma: from opinion to control [J].Drugs, 2009,69(9): 1189-1204.
5Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective [J]. J Clin Pharmacol, 2004,44(1): 37-47.
6Derendorf H, Nave R, Drollmann A, et al. Relevanceof pharmacokinetics and pharmacodynamics of inhaledcorticosteroids to asthma [J]. Eur Respir J, 2006, 28(5): 1042-1050.
7Bateman ED, Bousquet J, Keech ML, et al. The correlationbetween asthma control and health status: the GOAL study[J]. Eur Respir J, 2007, 29(1): 56-62.
8Lundback B, Ronmark E, Lindberg A, et al. Asthma controlover 3 years in a real-life study [J]. Respir Med, 2009, 103(3):348-355.
9Pasha MA, Smith TC, Feustel PJ, et al. Effects of low-dosefluticasone propionate/salmeterol combination therapy onexhaled nitric oxide and nitrite/nitrate in breath condensatesfrom patients with mild persistent asthma [J]. J Asthma, 2013,50(1): 64-70.
10Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief inmild-to-moderate asthma: a randomized, double-blind trial[J]. Chest, 2006, 129(2): 246-256.
